136 related articles for article (PubMed ID: 30370647)
1. Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro.
Shen L; Wang J; Yi Y; Ye C; Wang R; Xia G; Yu C; Tu F; Xu J; Zheng Z
Drug Test Anal; 2019 Apr; 11(4):595-600. PubMed ID: 30370647
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats.
Wang L; Wang S; Chen M; Chen X; Lin Y; Hu X; Huang X; Li X; Hu G
Drug Dev Ind Pharm; 2015; 41(10):1661-6. PubMed ID: 25417773
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC-MS/MS.
Xia M; Song X; Lu Z; Wang Y; Zhou Q; Geng P; Wang S; Zhou Y; Wu Q; Han A
Thorac Cancer; 2023 Nov; 14(33):3331-3341. PubMed ID: 37771131
[TBL] [Abstract][Full Text] [Related]
4. Silibinin affects the pharmacokinetics of methadone in rats.
Pan PP; Wang J; Luo J; Wang SH; Zhou YF; Chen SZ; Du Z
Drug Test Anal; 2018 Mar; 10(3):557-561. PubMed ID: 28643437
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the inhibitory effect of ketoconazole, voriconazole, fluconazole, and itraconazole on the pharmacokinetics of bosentan and its corresponding active metabolite hydroxy bosentan in rats.
Chen M; Zhang X; Chen Y; Sun W; Wang Z; Huang C; Hu G; Chen R
Xenobiotica; 2020 Mar; 50(3):280-287. PubMed ID: 31199171
[TBL] [Abstract][Full Text] [Related]
6. Isavuconazole and voriconazole inhibition of sterol 14α-demethylases (CYP51) from Aspergillus fumigatus and Homo sapiens.
Warrilow AGS; Parker JE; Price CL; Rolley NJ; Nes WD; Kelly DE; Kelly SL
Int J Antimicrob Agents; 2019 Oct; 54(4):449-455. PubMed ID: 31310805
[TBL] [Abstract][Full Text] [Related]
7. Effects of ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of apatinib in rats.
Lou D; Cui X; Bao SS; Sun W; Pan WH; Chen MC; Dong YY; Hu GX; Chen RJ; Wang Z
Drug Dev Ind Pharm; 2019 Apr; 45(4):689-693. PubMed ID: 30632818
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
Astvad KMT; Hare RK; Arendrup MC
Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.
Lin G; Wang C; Qiu X; Wang Z; Han A; Xu T; Kan X; Hu G
Drug Dev Ind Pharm; 2014 Dec; 40(12):1616-22. PubMed ID: 24053419
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal activity of isavuconazole against Madurella mycetomatis.
Kloezen W; Meis JF; Curfs-Breuker I; Fahal AH; van de Sande WW
Antimicrob Agents Chemother; 2012 Nov; 56(11):6054-6. PubMed ID: 22964246
[TBL] [Abstract][Full Text] [Related]
11. Studies on the inhibitory effect of isavuconazole on flumatinib metabolism
Liu YN; Xu X; Nie J; Hu Y; Xu X; Xu RA; Du X
Front Pharmacol; 2023; 14():1168852. PubMed ID: 37214442
[TBL] [Abstract][Full Text] [Related]
12. [In vitro susceptibility of cryptic species of Aspergillus fumigatus to isavuconazole, itraconazole and voriconazole by means of E-test].
Falces-Romero I; Quiles-Melero I; García-Rodríguez J
Rev Iberoam Micol; 2018; 35(2):113-114. PubMed ID: 29622510
[No Abstract] [Full Text] [Related]
13. Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.
Andes D; Kovanda L; Desai A; Kitt T; Zhao M; Walsh TJ
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735569
[TBL] [Abstract][Full Text] [Related]
14. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
15. Interaction between flucloxacillin and azoles: Is isavuconazole next?
Van Daele R; Wauters J; Vandenbriele C; Lagrou K; Vos R; Debaveye Y; Spriet I
Mycoses; 2021 Dec; 64(12):1508-1511. PubMed ID: 34553797
[TBL] [Abstract][Full Text] [Related]
16.
Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
[TBL] [Abstract][Full Text] [Related]
17. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological profile of isavuconazole].
Azanza Perea JR; Sádaba Díaz de Rada B
Rev Iberoam Micol; 2018; 35(4):186-191. PubMed ID: 30477963
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
[TBL] [Abstract][Full Text] [Related]
20. Quantification of Serum Voriconazole, Isavuconazole, and Posaconazole by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS).
Smith A; Dowis J; French D
Curr Protoc Toxicol; 2018 May; 76(1):e47. PubMed ID: 30040225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
